Welcome to our dedicated page for Precision Biosciences news (Ticker: DTIL), a resource for investors and traders seeking the latest updates and insights on Precision Biosciences stock.
Precision BioSciences, Inc. reports developments for a clinical-stage gene editing company using its proprietary ARCUS platform to develop in vivo therapies for diseases with high unmet need. Company news centers on PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy, including clinical-program updates, regulatory clearances and designations, scientific-meeting presentations, and data from the ELIMINATE-B and FUNCTION-DMD studies.
Recurring updates also include quarterly financial results, cash runway commentary, business priorities, and equity-compensation grants under Nasdaq inducement-award rules. Precision describes ARCUS applications across gene elimination, excision, and insertion, with program-specific disclosures tied to viral DNA, cccDNA, defective-gene removal, and AAV delivery.
DURHAM, N.C., Sept. 28, 2020 – Precision BioSciences, a clinical stage biotechnology company listed on Nasdaq as DTIL, announced its participation in two upcoming virtual investor conferences. The events include the Chardan 4th Annual Genetic Medicines Conference on October 5, 2020, from 8:30 – 9:00 AM ET, and the Jefferies Cell Therapy Summit, also on the same day, from 5:30 – 6:00 PM ET. Webcasts of the presentations will be available on the company's website, with an archived replay accessible for about 30 days post-event.
Precision BioSciences (Nasdaq: DTIL), a clinical-stage biotechnology company, announced its participation in two virtual investor conferences on October 5, 2020. The conferences include the Chardan 4th Annual Genetic Medicines Conference, scheduled for 8:30 AM ET, and the Jefferies Cell Therapy Summit, starting at 5:30 PM ET. Live webcasts will be accessible on the company’s website, with archived replays available for 30 days post-event. Precision BioSciences utilizes its ARCUS genome editing platform to develop innovative therapies for genetic and infectious diseases.
Precision BioSciences (Nasdaq: DTIL) announced a clinical trial collaboration with SpringWorks Therapeutics (Nasdaq: SWTX) to evaluate PBCAR269A, an allogeneic CAR T cell therapy targeting BCMA, in combination with nirogacestat, a gamma secretase inhibitor. The trial aims to improve outcomes in relapsed or refractory multiple myeloma patients and is set to commence in early 2021. Precision will cover all development costs, with the FDA granting Fast Track Designation to PBCAR269A. This collaboration seeks to enhance the efficacy of BCMA-targeted therapies through combined treatment strategies.
Precision BioSciences (Nasdaq: DTIL) expands its CAR T development agreement with Servier, adding two hematological and two solid tumor targets to its pipeline. This collaboration enhances the ongoing development of PBCAR0191, targeting CD19 in treating non-Hodgkin lymphoma and B-cell precursor acute lymphoblastic leukemia. Precision aims to utilize its ARCUS genome editing platform for early-stage research, with potential milestone payments expected in 2020 and 2021. The partnership aims to innovate 'off-the-shelf' CAR T therapies for broader cancer treatment applications.
Precision BioSciences has received Fast Track Designation from the FDA for its CAR T cell therapy, PBCAR269A, aimed at treating relapsed/refractory multiple myeloma. This designation follows the previously granted Orphan Drug Designation, expediting the clinical development process. PBCAR269A is undergoing a Phase 1/2a trial, with a focus on assessing safety and efficacy at escalating doses. The company leverages its proprietary ARCUS technology to optimize CAR T therapies, ultimately aiming to make treatments more accessible for patients.
Precision BioSciences (Nasdaq: DTIL) announced its participation in three upcoming investor conferences, showcasing its ARCUS® genome editing platform. The schedule includes the Wells Fargo Virtual Healthcare Conference on September 10, 2020, at 12:40 PM ET, the H.C. Wainwright Annual Global Investment Conference on September 14, 2020, at 1:30 PM ET, and the Morgan Stanley Global Healthcare Conference on September 17, 2020, at 8:45 AM ET. Live webcasts will be available on the company’s website, with replays accessible for 30 days.
Precision BioSciences (Nasdaq: DTIL) announced its Q2 2020 financial results and updates on clinical trials. The company initiated a Phase 1/2a trial for PBCAR269A, a CAR T candidate for multiple myeloma. However, patient enrollment delays related to COVID-19 have postponed updated interim data for PBCAR0191 until Q4 2020. Financially, total revenue decreased to $1.1 million from $5.4 million YoY, driven by reduced collaboration revenue. Operating expenses rose, resulting in a net loss of $32.7 million, or $(0.63) per share, compared to $(0.39) per share in 2019.
Precision BioSciences, a clinical-stage biotechnology firm, is set to report its Q2 2020 financial results on August 13, 2020. The company's ARCUS® genome editing platform aims to enhance therapeutic safety and efficacy, focusing on CAR T immunotherapy and gene correction therapies for genetic diseases. Additionally, CEO Matt Kane and CMO Chris Heery will represent the company at the William Blair Biotech Focus Conference on August 6 and the BTIG Virtual Biotechnology Conference on August 10. Live presentations will be available on their official website.
Precision BioSciences (Nasdaq: DTIL) announced it will regain full rights to its in vivo chronic hepatitis B virus (HBV) program previously developed in collaboration with Gilead Sciences. The company valued the collaboration, which is set to conclude on September 4, 2020, and anticipates no changes to its cash runway. As of March 31, 2020, cash and cash equivalents stood at $154.2 million, expected to fund operations into mid-2021. ARCUS gene editing has shown promise in targeting HBV, with preclinical data demonstrating significant effectiveness in knocking down HBV genomes.
Precision BioSciences (Nasdaq: DTIL) has initiated a Phase 1/2a clinical trial for its third allogeneic CAR T therapy candidate, PBCAR269A, targeting relapsed/refractory multiple myeloma. The first patient has been dosed, with the trial emphasizing the use of clinical materials produced at the company's in-house facility. PBCAR269A has shown promise in preclinical models, effectively reducing BCMA+ tumor cells without causing graft-versus-host disease. The FDA has granted it Orphan Drug Designation for multiple myeloma treatment.